SUMOylation occurs in acute kidney injury and plays a cytoprotective role

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 3, 2015, Pages 482-489

  Guo, Chunyuan ^a   Wei, Qingqing ^a   Su, Yunchao ^a   Dong, Zheng ^a,b,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Cisplatin nephrotoxicity; P53; Renal ischemia reperfusion; ROS; SUMOylation

Indexed keywords

ACETYLCYSTEINE; CISPLATIN; DIMETHYLUREA; GINKGOLIC ACID; GINKGOLIDE DERIVATIVE; PIFITHRIN ALPHA; PROTEIN P53; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; SALICYLIC ACID DERIVATIVE; SCAVENGER;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INCUBATION TIME; KIDNEY ISCHEMIA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT; REPERFUSION INJURY; SUMOYLATION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; PATHOLOGY;

MUS; RATTUS;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; FREE RADICAL SCAVENGERS; HEK293 CELLS; HUMANS; KIDNEY TUBULES, PROXIMAL; MICE; OXIDATIVE STRESS; RATS; SALICYLATES; SUMO-1 PROTEIN; SUMOYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920093315     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.12.013     Document Type: Article

References (55)

1. Faubel S., Chawla L.S., Chertow G.M., Goldstein S.L., Jaber B.L., Liu K.D. Acute kidney injury advisory group of the American Society of, ongoing clinical trials in AKI. Clin. J. Am. Soc. Nephrol. 2012, 7:861-873.
2. Lameire N.H., Bagga A., Cruz D., De Maeseneer J., Endre Z., Kellum J.A., Liu K.D., Mehta R.L., Pannu N., Van Biesen W., Vanholder R. Acute kidney injury: an increasing global concern. Lancet 2013, 382:170-179.
3. Bonventre J.V., Yang L. Cellular pathophysiology of ischemic acute kidney injury. J. Clin. Invest. 2011, 121:4210-4221.
4. Molitoris B.A. Therapeutic translation in acute kidney injury: the epithelial/endothelial axis. J. Clin. Invest. 2014, 124:2355-2363.
5. Gomez H., Ince C., De Backer D., Pickkers P., Payen D., Hotchkiss J., Kellum J.A. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014, 41:3-11.
6. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73:994-1007.
7. Miller R.P., Tadagavadi R.K., Ramesh G., Reeves P.G. Mechanisms of cisplatin nephrotoxicity. Toxins 2010, 2:2490-2518.
8. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23:460-464.
9. Linkermann A., Chen G., Dong G., Kunzendorf U., Krautwald S., Dong Z. Regulated cell death in AKI. J. Am. Soc. Nephrol. 2014, 25:2689-2701.
10. Havasi A., Borkan S.C. Apoptosis and acute kidney injury. Kidney Int. 2011, 80:29-40.
11. Cubenas-Potts C., Matunis M.J. SUMO: a multifaceted modifier of chromatin structure and function. Dev. Cell 2013, 24:1-12.
12. Hickey C.M., Wilson N.R., Hochstrasser M. Function and regulation of SUMO proteases. Nat. Rev. Mol. Cell Biol. 2012, 13:755-766.
13. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
14. Saitoh H., Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J. Biol. Chem. 2000, 275:6252-6258.
15. Galanty Y., Belotserkovskaya R., Coates J., Polo S., Miller K.M., Jackson S.P. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 2009, 462:935-939.
16. Qu J., Liu G., Wu K., Han P., Wang P., Li J., Zhang X., Chen C. Nitric oxide destabilizes Pias3 and regulates sumoylation. PLoS One 2007, 2:e1085.
17. Bossis G., Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol. Cell 2006, 21:349-357.
18. Shao R., Zhang F., Tian F., Anders Friberg P., Wang X., Sjoland H., Billig H. Increase of SUMO-1 expression in response to hypoxia: direct interaction with HIF-1alpha in adult mouse brain and heart in vivo. FEBS Lett. 2004, 569:293-300.
19. Manza L., Codreanu S., Stamer S., Smith D., Wells K., Roberts R., Liebler D. Global shifts in protein sumoylation in response to electrophile and oxidative stress. Chem. Res. Toxicol. 2004, 17:1706-1715.
20. Brooks C., Wei Q., Cho S., Dong Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J. Clin. Invest. 2009, 119:1275-1285.
21. Pabla N., Dong G., Jiang M., Huang S., Kumar M.V., Messing R.O., Dong Z. Inhibition of PKCdelta reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J. Clin. Invest. 2011, 121:2709-2722.
22. Pabla N., Huang S., Mi Q.S., Daniel R., Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J. Biol. Chem. 2008, 283:6572-6583.
23. Jiang M., Wei Q., Dong G., Komatsu M., Su Y., Dong Z. Autophagy in proximal tubules protects against acute kidney injury. Kidney Int. 2012, 82:1271-1283.
24. Zhang D., Liu Y., Wei Q., Huo Y., Liu K., Liu F., Dong Z. Tubular p53 regulates multiple genes to mediate acute kidney injury. J. Am. Soc. Nephrol. 2014, 25:2278-2289.
25. Wei Q., Dong G., Huang S., Ramesh G., Dong Z. Global deletion of Bak and specific deletion of Bax from proximal tubules protect against ischemic acute kidney injury in mice. Kidney Int. 2013, 84:138-148.
26. W.J., B.A. Molitoris, M.A. Venkatachalam, R.A. Zager, K.A. Nath, M.S. Goligorsky (discussants), in: W. Lieberthal, S.K. Nigam (Eds.), Acute renal failure. II. Experimental models of acute renal failure: imperfect but indispensable, Am. J. Physiol. Ren. Physiol. 278 (2000) F1-F12.
27. Yang Y., Liu H., Liu F.Y., Dong Z. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity. Arch. Toxicol. 2014, 88:1249-1256.
28. Liu H., Baliga R. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003, 63:1687-1696.
29. Xu Z., Lam L.S., Lam L.H., Chau S.F., Ng T.B., Au S.W. Molecular basis of the redox regulation of SUMO proteases: a protective mechanism of intermolecular disulfide linkage against irreversible sulfhydryl oxidation. FASEB J. 2008, 22:127-137.
30. Sahin U., Ferhi O., Jeanne M., Benhenda S., Berthier C., Jollivet F., Niwa-Kawakita M., Faklaris O., Setterblad N., de Thé H., Lallemand-Breitenbach V. Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins. J Cell Biol. 2014, 204:931-945.
31. Jiang M., Wei Q., Pabla N., Dong G., Wang C., Yang T., Smith S., Dong Z. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem. Pharmacol. 2007, 73:1499-1510.
32. Wei Q., Dong G., Yang T., Megyesi J., Price P.M., Dong Z. Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am. J. Physiol. Ren. Physiol. 2007, 293:F1282-F1291.
33. Lee Y.J., Mou Y., Maric D., Klimanis D., Auh S., Hallenbeck J.M. Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One 2011, 6:e25852.
34. Guo C., Hildick K.L., Luo J., Dearden L., Wilkinson K.A., Henley J.M. SENP3-mediated deSUMOylation of dynamin-related protein 1 promotes cell death following ischaemia. EMBO J. 2013, 32:1514-1528.
35. Datwyler A.L., Lattig-Tunnemann G., Yang W., Paschen W., Lee S.L., Dirnagl U., Endres M., Harms C. SUMO2/3 conjugation is an endogenous neuroprotective mechanism. J. Cereb. Blood Flow Metab. 2011, 31:2152-2159.
36. Fukuda I., Ito A., Hirai G., Nishimura S., Kawasaki H., Saitoh H., Kimura K., Sodeoka M., Yoshida M. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 2009, 16:133-140.
37. Tossidou I., Himmelseher E., Teng B., Haller H., Schiffer M. SUMOylation determines turnover and localization of nephrin at the plasma membrane. Kidney Int. 2014, 86:1161-1173.
38. Dasso M. Emerging roles of the SUMO pathway in mitosis. Cell Div. 2008, 3:5.
39. Hilgarth R.S., Murphy L.A., Skaggs H.S., Wilkerson D.C., Xing H., Sarge K.D. Regulation and function of SUMO modification. J. Biol. Chem. 2004, 279:53899-53902.
40. Krumova P., Weishaupt J.H. Sumoylation in neurodegenerative diseases. Cell. Mol. Life Sci. 2013, 70:2123-2138.
41. Flotho A., Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem. 2013, 82:357-385.
42. Yang X.J., Chiang C.M. Sumoylation in gene regulation, human disease, and therapeutic action, F1000prime reports 2013, 5:45.
43. Feligioni M., Nistico R. SUMO: a (oxidative) stressed protein. Neruomol. Med. 2013, 15:707-719.
44. Brooks C., Wang J., Yang T., Dong Z. Characterization of cell clones isolated from hypoxia-selected renal proximal tubular cells. Am. J. Physiol. Ren. Physiol. 2007, 292:F243-F252.
45. Yang W., Sheng H., Warner D.S., Paschen W. Transient focal cerebral ischemia induces a dramatic activation of small ubiquitin-like modifier conjugation. J. Cereb. Blood Flow Metab. 2008, 28:892-896.
46. Yang W., Sheng H., Warner D.S., Paschen W. Transient global cerebral ischemia induces a massive increase in protein sumoylation. J. Cereb. Blood Flow Metab. 2007, 28:269-279.
47. Cimarosti H., Lindberg C., Bomholt S.F., Rønn L.C.B., Henley J.M. Increased protein SUMOylation following focal cerebral ischemia. Neuropharmacology 2008, 54:280-289.
48. Tempe D., Piechaczyk M., Bossis G. SUMO under stress. Biochem. Soc. Trans. 2008, 36:874-878.
49. Baliga R., Ueda N., Walker P., Shah S. Oxidant mechanisms in toxic acute renal failure. Drug Metab. Rev. 1999, 31:971-997.
50. Kruidering M., Van De Water B., De Heer E., Mulder G.J., Nagelkerke J.F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J. Pharmacol. Exp. Ther. 1997, 280:638-649.
51. Siddik Z. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
52. Santos N.A.G., Bezerra C.S.C., Martins N.M., Curti C., Bianchi M.L.P., Santos A.C. Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother. Pharmacol. 2007, 61:145-155.
53. Cho S.G., Du Q., Huang S., Dong Z. Drp1 dephosphorylation in ATP depletion-induced mitochondrial injury and tubular cell apoptosis. Am. J. Physiol. Ren. Physiol. 2010, 299:F199-F206.
54. Culver C., Sundqvist A., Mudie S., Melvin A., Xirodimas D., Rocha S. Mechanism of hypoxia-induced NF-kappaB. Mol. Cell. Biol. 2010, 30:4901-4921.
55. Brandl A., Wagner T., Uhlig K.M., Knauer S.K., Stauber R.H., Melchior F., Schneider G., Heinzel T., Kramer O.H. Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J. Mol. Cell Biol. 2012, 4:284-293.